Frank Milton Balis, M.D.
Frank Milton Balis, M.D.
Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
The Children's Hospital of Philadelphia
3501 Civic Center Blvd., Room CTRB4024
Philadelphia, PA 19104
3501 Civic Center Blvd., Room CTRB4024
Philadelphia, PA 19104
Office: 267-426-5414
Fax: 267-425-0113
Fax: 267-425-0113
Email:
balisf@email.CHOP.edu
balisf@email.CHOP.edu
Education:
B.S. (Zoology)
University of North Carolina, 1971.
M.D. (Medicine)
Vanderbilt University, 1975.
Permanent linkB.S. (Zoology)
University of North Carolina, 1971.
M.D. (Medicine)
Vanderbilt University, 1975.
Description of Clinical Expertise
Solid tumors in children, renal tumors in children, clinical pharmacology of anticancer drugsDescription of Research Expertise
Clinical pharmacology of anticancer drugsSelected Publications
Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Korf B, Widemann BC. : Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer 60(3): 396-401, 2013.Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE.: A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high grade gliomas and brainstem gliomas: A Pediatric Brain Tumor Consortium Study. J Neuro-Oncol 106: 643-9, 2012.
Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade-Bender J, Burke M, Weigel B, Stempak D, Balis FM Blaney SM.: A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res 18(21): 6011-22, 2012.
Lodish M, Dagalakis U, Chen C, Sinaii N, Whitcomb T, Aikin A, Dombi E, Marcus L, Widemann B, Fox E, Chuk M, Balis FM, Wells S, Jr, Stratakis CA. : 111 In-Octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents. J Clin Endocrinol Metab 97: E207-12, 2012.
Murphy RF, Komlodi-Pasztor E, Robey R, Balis FM, Farrell NP, Fojo T. : Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum resistant cells compared to cisplatin and oxaliplatin. Cell Cycle 11: 963-73, 2012.
Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Beyever E, Balis FM, Fox E. : A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer 59: 865-9, 2012.
Kim A, McCully C, Cruz R, Cole DE, Fox E, Balis FM, Widemann BC. : The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Invest New Drugs 30: 524-8, 2012.
Balis FM, Fox E. : Challenges of developing new drugs for childhood cancers. Clin Investig 2: 291-300, 2012.
Aplenc, R., Blaney, S. M., Strauss, L. C., Balis, F. M., Shusterman, S., Ingle, A. M., Agrawal, S., Sun, J., Wright, J. J., Adamson, P. C.: Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children''s oncology group phase I consortium. J Clin Oncol 29(7): 839-44, 2011.
Bagatell, R., Herzog, C. E., Trippett, T. M., Grippo, J. F., Cirrincione-Dall, G., Fox, E., Macy, M., Bish, J., Whitcomb, P., Aikin, A., Wright, G., Yurasov, S., Balis, F. M., Gore, L.: Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 17(3): 611-9, 2011.